Literature DB >> 27460483

[GnRH agonist in PCa patients with clinically significant pre-existing cardiovascular disease].

A Merseburger1, D Sedding2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27460483     DOI： 10.1007/s00120-016-0197-z

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  4 in total

Review 1.  [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].

Authors:  C Tschöpe; B Kherad; F Spillmann; C A Schneider; B Pieske; F Krackhardt
Journal:  Herz       Date:  2016-04-15       Impact factor: 1.443

Review 2.  Radiotherapy and Hormone Treatment in Prostate Cancer.

Authors:  Dirk Böhmer; Manfred Wirth; Kurt Miller; Volker Budach; Axel Heidenreich; Thomas Wiegel
Journal:  Dtsch Arztebl Int       Date:  2016-04-08       Impact factor: 5.594

Review 3.  Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis.

Authors:  Frank Kunath; Hendrik Borgmann; Anette Blümle; Bastian Keck; Bernd Wullich; Christine Schmucker; Danijel Sikic; Catharina Roelle; Stefanie Schmidt; Amr Wahba; Joerg J Meerpohl
Journal:  BMJ Open       Date:  2015-11-13       Impact factor: 2.692

4.  Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(-/-) mice.

Authors:  Anki Knutsson; Sabrina Hsiung; Selvi Celik; Sara Rattik; Ingrid Yao Mattisson; Maria Wigren; Howard I Scher; Jan Nilsson; Anna Hultgårdh-Nilsson
Journal:  Sci Rep       Date:  2016-05-18       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.